Therapeutics News and Research

RSS

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

NanoViricides, Inc. (the "Company"), reports that it has signed a research and development agreement with Dr. Eva Harris’s laboratory at the University of California, Berkeley (UC Berkeley).

17 Feb 2010

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, announced today that the US FDA has granted orphan drug designation for QPI-1002 (also referred to as "I5NP"), a synthetic siRNA targeting p53 mRNA for the prophylaxis of delayed graft function (DGF) in kidney transplant patients.

17 Feb 2010

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Celldex Therapeutics, Inc. today announced that it has received a sublicense income payment of $3 million from TopoTarget A/S as a result of the recent co-development and commercialization agreement between TopoTarget and Spectrum Pharmaceuticals, Inc. for Belinostat, a novel histone deacetylase (HDAC) inhibitor for the treatment of cancer.

17 Feb 2010

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

The new decade may herald an era of cell therapy -- treating human diseases by delivering highly specific beneficial cells. In the wake of an NIH decision late last year permitting federally funded researchers to use new lines of human embryonic stem cells, the door has opened more widely to stem cell research.

16 Feb 2010

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

Two teams from the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University received significant support from the Canadian Institutes of Health Research (CIHR) amounting to $5 million over five years.

15 Feb 2010

U.S. Court rules in favor of Perrigo over Mucinex patent litigation

Perrigo Company announced today that a federal court has granted summary judgment in its favor in patent litigation involving Guaifenesin Extended-Release Tablets, 600 mg, a generic version of Mucinex® tablets. Perrigo had been sued by Adams Respiratory Therapeutics, Inc., (a subsidiary of Reckitt Benckiser Group plc.) the New Drug Application holder and patent owner. The United States District Court for the Western District of Michigan ruled today that Perrigo does not infringe the patent in the suit. Perrigo's ANDA is awaiting FDA approval.

12 Feb 2010

Gold nanoparticles for cancer treatment

World Gold Council (WGC) has today published 'Gold for Good: Gold and nanotechnology in the age of innovation', a research paper detailing new scientific and technological innovations using gold. The report, which was produced in conjunction with Cientifica Ltd, the world's leading source of global business and investor intelligence about nanotechnologies, demonstrates how gold nanoparticles offer the potential to overcome many of the serious issues facing mankind over the coming decades.

12 Feb 2010

Second-quarter fiscal 2010 results announced by Pharmacyclics

Pharmacyclics, Inc. today reported financial results for its second fiscal quarter ended December 31, 2009.

12 Feb 2010

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, and Ascentage Pharma Group Corporation, Ltd. ("Ascentage Pharma") announced today that they have formed a strategic alliance to research, develop and commercialize best-in-class targeted cancer therapeutics focusing on programmed cell death, or apoptosis. The alliance will leverage Ascentage Pharma's expertise in structure-based small molecule design, lead optimization and preclinical development with 3SBio's proven drug development and commercialization capabilities in China.

12 Feb 2010

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics announced today additional positive preliminary data from its ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease at the Lysosomal Disease Network WORLD Symposium in Miami, Florida.

11 Feb 2010

Excelimmune receives $1M investment as part of open Series-B financing round

Excelimmune, Inc. announced today they have received a $1 million investment as part of an open Series-B financing round. The investment comes from a mixture of existing and new investors.

11 Feb 2010

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant.

11 Feb 2010

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

Companies in the Life Sciences sector, which includes the biotechnology and medical device industries, captured the largest share of overall venture capital during 2009, reflecting the relative strength of the sector during the economic downturn, according to PricewaterhouseCoopers LLP (PwC).

11 Feb 2010

CTI reports financial results for fourth-quarter and year ended December 31, 2009

Cell Therapeutics, Inc. (CTI) today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2009.

11 Feb 2010

ExonHit Therapeutics S.A. selected to participate in the European IMI consortium

ExonHit Therapeutics S.A. is pleased to announce that it has been chosen to participate in the European Innovative Medicines Initiative (IMI) consortium focused on identifying biomarkers for Alzheimer’s disease (PharmaCog).

11 Feb 2010

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Shenogen Pharma Group and Chemizon, a division of Optomagic Co. Ltd. today announced a drug discovery collaboration agreement to create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.

11 Feb 2010

Seaside Therapeutics granted U.S patent covering methods of treating autism

Seaside Therapeutics LLC today announced the issuance of U.S. patent 7,648,993 B2 (‘993 patent), which covers methods of treating autism with group 1 antagonists of the metabotropic glutamate receptor (mGluR) pathway. An earlier related patent, U.S. patent 6,890,931 B2 (‘931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome, the most common known cause of autism, with group 1 antagonists of the mGluR pathway.

10 Feb 2010

Glide Pharma to utilize $4.3M funding for progressing octreotide programme into clinical development

Glide Pharma, a specialty pharmaceutical company focused on the needle-free administration of solid dose therapeutics and vaccines, today announced that it has completed an oversubscribed GBP2.7 million ($4.3 million) investment round. The fundraising was supported by a number of existing institutional and private investors, including Hygea VCT and Oxford Technology VCTs. The company has now completed four successful investment rounds, securing funding totalling approximately GBP10 million.

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.

10 Feb 2010

Therapeutics News and Research

NanoViricides signs research and development agreement with Dr. Eva Harris’s laboratory at UC Berkeley

Quark Pharmaceuticals' QPI-1002 receives orphan drug designation from FDA

TopoTarget pays Celldex Therapeutics $3M sublicense income over Belinostat co-development agreement

Children's Hospital of Philadelphia awarded two grants to research into cellular therapies for blood disorders

RI-MUHC and McGill University teams receive $5M CIHR grant for environmental and reproductive health studies

U.S. Court rules in favor of Perrigo over Mucinex patent litigation

Gold nanoparticles for cancer treatment

Second-quarter fiscal 2010 results announced by Pharmacyclics

3SBio, Ascentage Pharma announce cancer therapeutics collaboration

Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease

Excelimmune receives $1M investment as part of open Series-B financing round

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

PwC: Companies in Life Sciences sector captured largest share of overall venture capital during 2009

CTI reports financial results for fourth-quarter and year ended December 31, 2009

ExonHit Therapeutics S.A. selected to participate in the European IMI consortium

Shenogen Pharma Group, Chemizon sign drug discovery collaboration agreement

Seaside Therapeutics granted U.S patent covering methods of treating autism

Glide Pharma to utilize $4.3M funding for progressing octreotide programme into clinical development

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News